Merck
CN

Cimetidine: an anticancer drug?

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences (2011-02-19)
Martina Kubecova, Katarina Kolostova, Daniela Pinterova, Grzegorz Kacprzak, Vladimir Bobek
ABSTRACT

Cimetidine, H(2) receptor antagonists, is commonly prescribed for gastric and duodenal ulcer disease. Additionally, cimetidine has been shown to have anticancer effects. This review describes the mechanism of antitumor action of cimetidine including its ability to interfere with tumor cell adhesion, angiogenesis and proliferation; its effect on the immune system; as well as inhibition of postoperative immunosuppression. Its anticancer effect is also compared to that of the other H(2) receptor antagonists as well as outcomes of cimetidine in clinical studies in cancer patients.

MATERIALS
Product Number
Brand
Product Description

Cimetidine, European Pharmacopoeia (EP) Reference Standard
Supelco
Cimetidine, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Cimetidine
Cimetidine for peak identification, European Pharmacopoeia (EP) Reference Standard
Cimetidine for system suitability, European Pharmacopoeia (EP) Reference Standard